Miller, Riddell play key roles in UW gene therapy project

Hutch News

Miller, Riddell play key roles in UW gene therapy project

Feb. 1, 2001

Hutch scientists will be an important part of a $12.8 million project at the University of Washington to develop a Program of Excellence in Gene Therapy.

The five-year grant was awarded by the National Heart, Lung and Blood Institute of the National Institutes of Health. It will support research on both present and future uses of gene therapy.

Dr. Dusty Miller, an investigator in the Human Biology Division and an affiliate professor of pathology at UW, will co-direct a project to develop gene-therapy techniques for cystic fibrosis, a life-threatening disease that causes lung and digestive complications and is the most common genetic defect of its severity in the United States.

Dr. Stanley Riddell, a scientist in the Clinical Research Division and a UW professor of medicine, will direct a gene-therapy trial to reduce incidence of graft-vs.-host disease, a complication of bone-marrow transplantation.

Other components of the program include basic research to explore stem-cell gene therapy, gene therapy for the blood disorders sickle-cell anemia and thalessemia.

In addition, an educational component will offer a gene-therapy training program for postdoctoral researchers.

No tags to display. Taglist will not be shown.

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.